Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: Piperacillin-tazobactam as compared with cefepime

Clinical Microbiology and Infection

Volumn 20, Issue 6, 2014, Pages

  Moenster, R P ^a,b   Linneman, T W ^a,b   Finnegan, P M ^a,b   Hand, S ^b   Thomas, Z ^b   Mcdonald, J R ^a  

^a VA St Louis Healthcare System   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Acute renal failure; Osteomyelitis; Vancomycin; lactams

Indexed keywords

CEFEPIME; CREATININE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC PATIENT; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NEUTROPHIL COUNT; OSTEOMYELITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES COMPLICATIONS; INCIDENCE; MIDDLE AGED; PROCEDURES;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COHORT STUDIES; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOMYELITIS; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84904427288     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12410     Document Type: Article

References (25)

1. Diabetes.org. Diabetes statistics. Available from: http://www.diabetes.org/diabetes-basics/diabetes-statistics (last accessed 3 September 2011).
2. Hartemann-Heurtier A, Senneville E. Diabetic foot osteomyelitis. Diabete Metab 2008; 34: 87-95.
3. Nicolau DP, Stein GE. Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. J Am Podiatr Med Assoc 2010; 100: 52-63.
4. Rao N, Ziran BH, Lipsky BA. Treating osteomyelitis: antibiotics and surgery. Plast Reconstr Surg 2011; 127(suppl 1): 177S-187S.
5. Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910.
6. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37: 95-101.
7. Appel GB, Given DB, Levine LR, Cooper GL. Vancomycin and the kidney. Am J Kidney Dis 1986; 8: 75-80.
8. Rybak M, Lomaestro B, Rotschaefer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-Systems Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
9. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner J, Forescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010; 9: 9-14.
10. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010; 123: 1143-1149.
11. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-687.
12. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107-1115.
13. Horey A, Mergenhagen KA, Mattappallil A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann Pharmacother 2012; 46: 1477-1483.
14. Van Hal SJ, Paterson DL, Lodise TP. Vancomycin-induced nephrotoxicity in troughs of '15-20' mcg/mL era: a systematic review and meta-analysis. Antimicrob Agents Chemother 2012; doi:10.1128/AAC.01568-12.
15. Jensen JU, Hein L, Lundgren B et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomized trial. BMJ Open 2012; 2: e000635.
16. Schmitt DV, Leitner E, Welte T, Lode H. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of nosocomial pneumonia-a double blind prospective multicentre study. Infection 2006; 34: 127-134.
17. Brun-Buisson C, Sollet JB, Schweich H, Briere S, Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis 1998; 26: 346-354.
18. Jaccard C, Troillet CJ, Harbarth S et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-2972.
19. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27: 493-502.
20. Saltoglu N, Dalkiran A, Tetiker T et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect 2010; 16: 1252-1257.
21. Sabra R, Branch RA. Role of sodium in protection by extended-spectrum penicillins against tobramycin-induced nephrotoxicity. Antimicrob Agents Chemother 1990; 34: 1020-1025.
22. Hayashi T, Watanabe Y, Kumano K et al. Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats. Antimicrob Agents Chemother 1989; 33: 513-518.
23. Santos Navarro M, Zarzuelo Castaneda A, Lopez FG, Sanchez Navarro A, Arevalo M, Lanao JM. Pharmacokinetic parameters of netilmicin and protective effect of piperacillin regarding nephrotoxicity caused by netilmicin. Eur J Drug Metab Pharmacokinet 1998; 23: 143-147.
24. Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41: 1704-1708.
25. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 338-348.